Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Shares Outstanding (2020 - 2025)

Bolt Biotherapeutics' Shares Outstanding history spans 6 years, with the latest figure at $1.9 million for Q3 2025.

  • For Q3 2025, Shares Outstanding changed 0.3% year-over-year to $1.9 million; the TTM value through Sep 2025 reached $1.9 million, changed 0.3%, while the annual FY2024 figure was $38.3 million, 1911.79% up from the prior year.
  • Shares Outstanding for Q3 2025 was $1.9 million at Bolt Biotherapeutics, roughly flat from $1.9 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $38.3 million in Q1 2025 and bottomed at $1.9 million in Q4 2023.
  • The 5-year median for Shares Outstanding is $37.2 million (2021), against an average of $24.4 million.
  • The largest annual shift saw Shares Outstanding soared 1817.71% in 2021 before it tumbled 94.98% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $37.4 million in 2021, then rose by 1.06% to $37.8 million in 2022, then crashed by 94.96% to $1.9 million in 2023, then increased by 0.59% to $1.9 million in 2024, then rose by 0.13% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Shares Outstanding are $1.9 million (Q3 2025), $1.9 million (Q2 2025), and $1.9 million (Q1 2025).